ALT - Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024 | Benzinga
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Details for the presentations are as follows:
| Title: |
| Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model (abstract #2881) |
| Presenter: |
| Sarah Browne, M.D., Vice President, Clinical Development, Altimmune |
| Date/Time: |
| Wednesday, June 5, 2024, at 8:30 am CEST |